Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › ACHIEVE-4

ACHIEVE-4

Orforglipron · T2D at increased CV risk (86 % established CVD, 38 % CKD), t2d

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
Orforglipron
Population
T2D at increased CV risk (86 % established CVD, 38 % CKD), t2d
Official title
A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk
Sponsor
Eli Lilly and Company
Phase
3
Registry status
completed · 2023-04 → 2026-03
Participants
2749
Duration
52 weeks
Registry
NCT05803421

Results by arm

ArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
orforglipron 36 mg or MTD vs insulin glargine (active)t2d52—−8.8 %−7.8 %−1.515.430.9 vs 20.531.921.016.2—verified

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Notes

Verbatim quotes from the source (7)
  • orforglipron 36 mg or MTD · weight_eff · Table (week 52)
    52 | -8.76% | 1.66%
  • orforglipron 36 mg or MTD · hba1c · Table (week 52)
    Orforglipron | -1.46
  • orforglipron 36 mg or MTD · disc_any · Results, disposition
    2044 (74·4%) of 2749 completed the study on treatment (948 [69·1%] of 1371 assigned to orforglipron and 1096 [79·5%] of 1378 assigned to insulin glargine). The
  • orforglipron 36 mg or MTD · ae_dc · Table 3 (orforglipron n=1371, insulin glargine n=1355; on-tr
    Adverse events leading to study treatment discontinuation 211 (15·4%) 73 (5·4%)
  • orforglipron 36 mg or MTD · nausea · Table 3 (orforglipron n=1371, insulin glargine n=1355; on-tr
    Nausea 438 (31·9%) 19 (1·4%)
  • orforglipron 36 mg or MTD · vomiting · Table 3 (orforglipron n=1371, insulin glargine n=1355; on-tr
    Vomiting 288 (21·0%) 22 (1·6%)
  • orforglipron 36 mg or MTD · sae · Table 3 (orforglipron n=1371, insulin glargine n=1355; on-tr
    Serious adverse events 222 (16·2%) 255 (18·8%)

Cardiovascular and kidney outcomes

ACHIEVE-4 orforglipron 36 mg or maximum tolerated dose (oral, once daily) vs insulin glargine (active) · T2D at increased CV risk (86 % established CVD, 38 % CKD) · n = 2749 · 2026 verified

EndpointHR95 % CIEvents, drug vs controlStatus
4-point MACE primary
MACE-4: composite of non-fatal myocardial infarction, non-fatal stroke, hospitalisation for unstable angina, or cardiovascular death (primary endpoint; non-inferiority, safety analysis set)
0.840.59–1.2057 vs 67verified
3-point MACE
MACE-3: composite of non-fatal myocardial infarction, non-fatal stroke, or cardiovascular death (key secondary endpoint; superiority, randomised participants excluding GCP-closed sites)
0.770.52–1.1346 vs 59verified
Cardiovascular death
Cardiovascular death (component of MACE-4; deaths of undetermined cause counted as CV deaths)
0.470.25–0.9014 vs 29verified
Myocardial infarction
Non-fatal myocardial infarction (component of MACE-4) — non-fatal events only
0.850.46–1.5819 vs 22verified
Stroke
Non-fatal stroke (component of MACE-4) — non-fatal events only
0.980.47–2.0614 vs 14verified
Hospitalisation for unstable angina
Hospitalisation for unstable angina (component of MACE-4)
1.550.67–3.5814 vs 9verified
Verbatim quotes (6)
  • 4-point MACE · Table 2
    p value MACE-4 (primary endpoint)* 57/1358 (4·2%) 67/1343 (5·0%) 0·84 (0·59-1·20)
  • 3-point MACE · Table 2
    47-2·06) ·· Hospitalisation for unstable angina 14/1358 (1·0%) 9/1343 (0·7%) 1·55 (0·67-3·58) ·· MACE-3 (key secondary endpoint)* 46/1358 (3·4%) 59/1366 (4·3%) 0·77 (0·52-1·13)
  • Cardiovascular death · Table 2
    p value MACE-4 (primary endpoint)* 57/1358 (4·2%) 67/1343 (5·0%) 0·84 (0·59-1·20) <0·0001 (non- inferiority) Cardiovascular death 14/1358 (1·0%) 29/1343 (2·2%) 0·47 (0·25-0·90)
  • Myocardial infarction · Table 2
    <0·0001 (non- inferiority) Cardiovascular death 14/1358 (1·0%) 29/1343 (2·2%) 0·47 (0·25-0·90) ·· Non-fatal myocardial infarction 19/1358 (1·4%) 22/1343 (1·6%) 0·85 (0·46-1·58)
  • Stroke · Table 2
    343 (2·2%) 0·47 (0·25-0·90) ·· Non-fatal myocardial infarction 19/1358 (1·4%) 22/1343 (1·6%) 0·85 (0·46-1·58) ·· Non-fatal stroke 14/1358 (1·0%) 14/1343 (1·0%) 0·98 (0·47-2·06)
  • Hospitalisation for unstable angina · Table 2
    (1·6%) 0·85 (0·46-1·58) ·· Non-fatal stroke 14/1358 (1·0%) 14/1343 (1·0%) 0·98 (0·47-2·06) ·· Hospitalisation for unstable angina 14/1358 (1·0%) 9/1343 (0·7%) 1·55 (0·67-3·58)

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: ACHIEVE-4. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/achieve-4/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.